Title

The clinical march of bNAbs

Code

OA03

Session Type

Oral Abstract

Channel

Live channel 1

Date Time

Wednesday 27 January, 17:30 - 18:30 (UTC)

Co-Chairs:

Marina CASKEY, The Rockefeller University, United States
Alexandra TRKOLA, Institute of Medical Virology, Switzerland

OA03.01	Safety and single-dose pharmacokinetics of VRC07-523LS administered via different routes and doses Stephen WALSH, Brigham & Women's Hospital, United States	Abstract

OA03.02	Safety and PK of potent anti-HIV monoclonal AB VRC07-523LS in HIV-exposed infants Coleen CUNNINGHAM, Duke University School of Medicine, United States	Abstract

OA03.05	Neutralization profiles of HIV-1 subtype C breakthrough viruses from the Southern African VRC01 AMP trial (HVTN 703/HPTN 081) Nonhlanhla N. MKHIZE, National Institute for Communicable Diseases, South Africa	Abstract

OA03.04LB	Analysis of genetic diversity and VRC01 pressure on HIV-1 breakthrough viruses from the AMP trial (HVTN 703/HPTN 081 and HVTN 704/085) Carolyn WILLIAMSON, University of Cape Town, South Africa	Abstract

OA03.03LB	HIV-1 bnAb M4008_N1 targets a novel site of vulnerability at the V3 crown Kun-Wei CHAN, NYU School of Medicine, United States	Abstract

OA03.06	Live Q&A